Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (CERE) is a neuroscience-focused biopharmaceutical company that entered the public markets in 2020 through a merger with ARYA Sciences Acquisition Corp II, a blank-check vehicle sponsored by ARYA Sciences. The company concentrated on developing treatments for neurological and psychiatric conditions, including schizophrenia, Parkinson's disease, and epilepsy. An 8-K filed August 1, 2024 reflects Cerevel's status following AbbVie's acquisition of the company, a transaction announced in late 2023 that represented a significant exit event for SPAC-era shareholders. CERE's trajectory from SPAC combination to major-pharma acquisition illustrates the full lifecycle of a CNS-sector de-SPAC. Sign up for SpacDesk to access complete filing history, sponsor data, and deal analytics for CERE and hundreds of other SPACs.